In the latest trading session, 0.69 million IGM Biosciences Inc (NASDAQ:IGMS) shares changed hands as the company’s beta touched 0.17. With the company’s most recent per share price at $1.90 changed hands at -$0.19 or -9.09% at last look, the market valuation stands at $112.98M. IGMS’s current price is a discount, trading about -1084.21% off its 52-week high of $22.50. The share price had its 52-week low at $1.87, which suggests the last value was 1.58% up since then. When we look at IGM Biosciences Inc’s average trading volume, we note the 10-day average is 0.81 million shares, with the 3-month average coming to 322.62K.
Analysts gave the IGM Biosciences Inc (IGMS) stock a consensus recommendation rating of Hold, calculated at a mean rating of 3.20. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended IGMS as a Hold, 0 felt it is a Buy and 0 rated the stock as Underweight. IGM Biosciences Inc’s EPS for the current quarter is expected to be -0.77.
IGM Biosciences Inc (NASDAQ:IGMS) trade information
Instantly IGMS was in red as seen in intraday trades today. With action -71.04%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -68.90%, with the 5-day performance at -71.04% in the red. However, in the 30-day time frame, IGM Biosciences Inc (NASDAQ:IGMS) is -79.98% down. Looking at the short shares, we see there were 2.64 million shares sold at short interest cover period of 12.4 days.
The consensus price target for the stock as assigned by Wall Street analysts is 16.5, meaning bulls need an upside of 88.48% from its recent market value. According to analyst projections, IGMS’s forecast low is 1.5 with 25 as the target high. To hit the forecast high, the stock’s price needs a -1215.79% plunge from its current level, while the stock would need to tank 21.05% for it to hit the projected low.
IGM Biosciences Inc (IGMS) estimates and forecasts
Data shows that the IGM Biosciences Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -80.29% over the past 6 months, a 29.30% in annual growth rate that is considerably higher than the industry average of 16.40%. Year-over-year growth is forecast to reach 23.34% up from the last financial year.
Consensus estimates given by 9 financial analysts project the company’s revenue in the current quarter to hit an average of 366.67k. 3 analysts are of the opinion that IGM Biosciences Inc’s revenue for the current quarter will be 2.49M. The company’s revenue for the corresponding quarters a year ago was 651k and 497k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -43.68%. The estimates for the next quarter sales put growth at 400.47%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -44.65%. The 2025 estimates are for IGM Biosciences Inc earnings to increase by 32.32%.
IGMS Dividends
IGM Biosciences Inc is expected to release its next quarterly earnings report in February.
IGM Biosciences Inc (NASDAQ:IGMS)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 34.95% of IGM Biosciences Inc shares while 64.03% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 98.42%. There are 64.03% institutions holding the IGM Biosciences Inc stock share, with BAKER BROS. ADVISORS LP the top institutional holder. As of 2024-06-30, the company held 6.8042% of the shares, roughly 4.09 million IGMS shares worth $28.1 million.
PRICE T ROWE ASSOCIATES INC /MD/ holds the second largest percentage of outstanding shares, with 6.7789% or 4.08 million shares worth $28.0 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Price (T.Rowe) New Horizons Fund and Price (T.Rowe) Health Sciences Fund. With 1.97 shares estimated at $3.74 million under it, the former controlled 5.77% of total outstanding shares. On the other hand, Price (T.Rowe) Health Sciences Fund held about 2.49% of the shares, roughly 849.75 shares worth around $1.61 million.
